Latest Hotspot

Successful Phase 1 Results for TERN-601, a Daily Oral GLP-1R Agonist in Obesity Treatment

11 September 2024
3 min read

Terns Pharmaceuticals, Inc. ("Terns" or the "Company") (Nasdaq: TERN), a clinical-stage biopharmaceutical organization focusing on developing a series of small-molecule product candidates for serious diseases, has revealed positive top-line results from its Phase 1 randomized, double-blind, placebo-controlled single and multiple-ascending dose (SAD and MAD) study. This trial aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of once-daily (QD) administered TERN-601 in healthy adults who are either obese or overweight.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.

The findings from the clinical trial indicated that TERN-601 was well tolerated and showed a dose-responsive, significantly higher placebo-adjusted average weight loss across all three dosages examined in the 28-day MAD study. The highest placebo-adjusted average weight loss observed was 4.9% (p<0.0001) at the maximum dose of 740 mg QD. Furthermore, 67% of the participants achieved a reduction in their baseline body weight by 5% or more at the highest dose.

“These remarkable findings highlight TERN-601’s potential to become a leading GLP-1R agonist, given its preliminary signs of efficacy, tolerability, and potential for scalable manufacturing,” said Amy Burroughs, CEO of Terns. “This data substantiates the potential of TERN-601 for obesity treatment either as a stand-alone therapy or in combination with compounds like TERN-501, our internally developed, clinical-stage THR-β agonist, or a GIPR modulator from the TERN-800 series. With preparations actively in progress, we are excited to move this promising candidate swiftly into Phase 2 clinical trials by 2025.”

“We are pleased to showcase potent GLP-1R agonism with TERN-601, owing to its unique drug properties that allow sustained target engagement with once-daily dosing and evaluation of doses up to 740 mg, all while maintaining tolerability,” stated Emil Kuriakose, Chief Medical Officer of Terns. “Crucially, we believe we have identified an optimal range of clinically effective, well-tolerated doses to carry forward into Phase 2 clinical trials, with no need for further dose range exploration anticipated.”

👇Explore the most recent advancements in drug research, indications, organizations, clinical trials, results, and patents related to this target by clicking the image link below. Dive in to gain deeper insights!

图形用户界面, 文本, 应用程序

描述已自动生成

According to the data provided by the Synapse Database, As of September 11, 2024, there are 456 investigational drugs for the GLP-1R target, including 119 indications, 368 R&D institutions involved, with related clinical trials reaching 2739, and as many as 10350 patents.

TERN-601 is a small molecule drug developed by Terns Pharmaceuticals, Inc. The drug targets GLP-1R and has shown potential therapeutic effects in the areas of endocrinology and metabolic diseases, as well as digestive system disorders. Its active indications include obesity and MASH (a condition that involves the combination of non-alcoholic fatty liver disease and steatohepatitis).

图形用户界面, 文本, 应用程序

描述已自动生成

Preview of Clinical Results from ESMO 2024!
Feature Updates
3 min read
Preview of Clinical Results from ESMO 2024!
11 September 2024
The Synapse database immediately launched a search portal for ESMO clinical results data, facilitating user access.
Read →
IDeate-Lung01 Phase 2 Trial: Promising Response Rates with Ifinatamab Deruxtecan in Advanced Small Cell Lung Cancer
Latest Hotspot
3 min read
IDeate-Lung01 Phase 2 Trial: Promising Response Rates with Ifinatamab Deruxtecan in Advanced Small Cell Lung Cancer
11 September 2024
The IDeate-Lung01 Phase 2 Trial shows Ifinatamab Deruxtecan maintains encouraging objective response rates in patients with advanced-stage small cell lung cancer.
Read →
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Sep 11
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Sep 11
11 September 2024
Sep 11th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
GSK reports promising phase III trial outcomes for Nucala (mepolizumab) in treating COPD
Latest Hotspot
3 min read
GSK reports promising phase III trial outcomes for Nucala (mepolizumab) in treating COPD
10 September 2024
GSK plc (LSE/NYSE: GSK) released encouraging top-line outcomes from MATINEE in adult patients suffering from chronic obstructive pulmonary disease (COPD).
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.